Eupraxia Pharmaceuticals Inc. Common Stock EPRX

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

• GlobeNewswire Inc. 30 sept

  Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

  Eupraxia Pharmaceuticals announced positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE). The highest dose cohorts demonstrated durable symptom responses with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, and a favorable safety profile with no serious adverse events or oropharyngeal candidiasis reported. The company plans to report Phase 2b interim data in December 2026.

  

• GlobeNewswire Inc. 19 jun

  Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

  Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.